Skip to main content

Eli Lilly and Company (LLY)

NYSE: LLY · IEX Real-Time Price · USD
231.68 -0.50 (-0.22%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap221.62B
Revenue (ttm)26.73B
Net Income (ttm)6.07B
Shares Out907.30M
EPS (ttm)6.65
PE Ratio34.84
Forward PE26.25
Dividend$3.18 (1.37%)
Ex-Dividend DateAug 12, 2021
Volume1,642,578
Open232.77
Previous Close232.18
Day's Range231.34 - 235.47
52-Week Range127.04 - 275.87
Beta0.25
AnalystsBuy
Price Target266.88 (+15.2%)
Est. Earnings DateOct 26, 2021

About LLY

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for me...

IndustryPharmaceuticals
Founded1876
CEODavid Ricks
Employees34,657
Stock ExchangeNYSE
Ticker SymbolLLY
Full Company Profile

Financial Performance

In 2020, Eli Lilly's revenue was $24.54 billion, an increase of 9.95% compared to the previous year's $22.32 billion. Earnings were $6.19 billion, a decrease of -25.54%.

Financial Statements

Analyst Forecast

According to 19 analysts, the average rating for Eli Lilly stock is "Buy." The 12-month stock price forecast is 266.88, which is an increase of 15.19% from the latest price.

Price Target
$266.88
(15.19% upside)
Analyst Consensus: Buy

News

Eli Lilly and Company Issues Voluntary Nationwide Recall of One Lot of GLUCAGON® Emergency Kit Due to Loss of Potency

INDIANAPOLIS, Sept. 24, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) is voluntarily recalling lot D239382D, Expiration April 2022, of Glucagon Emergency Kit for Low Blood Sugar (Glucagon for I...

2 days ago - PRNewsWire

Where to Invest $10,000 in a Bear Market

For now, both of these high-quality companies may be a bit overvalued, but that could change.

Other symbols:MRNA
2 days ago - The Motley Fool

Lilly (LLY) to Supply COVID Cocktail Drug to EU Countries

Elli Lilly (LLY) is set to supply 220,000 doses of its COVID-19 antibody cocktail to European Union member nations, following approval.

4 days ago - Zacks Investment Research

Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount...

INDIANAPOLIS, Sept. 21, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the pricing terms of its previously announced cash tender offer for specified series of its outstanding deb...

5 days ago - PRNewsWire

Lilly announces procurement agreement with European Commission to supply bamlanivimab and etesevimab together for the...

INDIANAPOLIS, Sept. 21, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a Joint Procurement Agreement with the European Commission (EC) to supply up to 220,000 doses of bamlanivim...

5 days ago - PRNewsWire

Lilly Announces the Early Tender Results of Its Pending Cash Tender Offer for Up to $1.5 Billion Combined Aggregate P...

INDIANAPOLIS, Sept. 21, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the early tender results of its previously announced cash tender offer for specified series of its outstand...

5 days ago - PRNewsWire

Big Pharma Stocks Hit Hard by Drug Price Proposals

Drug stocks are in a tailspin, and you need to look no farther than Washington for the primary reason. A White House plan to cut the price of medications has led to a more than 10% drop in the Dow Jones...

Other symbols:BMYJNJMRKPFE
6 days ago - GuruFocus

Lilly (LLY) Gets FDA Nod for Expanded Use of COVID Cocktail

FDA revises Lilly's (LLY) EUA for COVID-19 antibody cocktail, bamlanivimab and etesevimab, for post-exposure prophylaxis for COVID-19.

1 week ago - Zacks Investment Research

AbCellera Stock Is Moving Higher After Expanded Use Nod For Lilly-Partnered COVID-19 Antibody

The FDA has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis in certain individuals to prevent SAR...

Other symbols:ABCL
1 week ago - Benzinga

Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-ex...

INDIANAPOLIS, Sept. 16, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered to...

1 week ago - PRNewsWire

Regeneron, Lilly Get New COVID Drug Deals From Government

Regeneron (REGN) is set to supply an additional 1.4 million doses of its antibody cocktail for COVID-19, REGEN-COV while Lilly (LLY) will supply 388,000 doses of its COVID-19 antibody medicine, etesevim...

Other symbols:REGN
1 week ago - Zacks Investment Research

Smart Investors Are Watching This Trend Right Now

It has to do with the coronavirus -- but it's not about vaccines.

Other symbols:PFEREGNVIR
1 week ago - The Motley Fool

After Regeneron, US Government Orders Additional COVID-19 Therapy From Eli Lilly

The U.S. government has announced to purchase additional doses of Eli Lilly And Co's (NYSE: LLY) for its neutralizing antibody therapies for COVID-19. Related Link: Distribution Resumes Of Eli Lilly COV...

1 week ago - Benzinga

Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19

INDIANAPOLIS, Sept. 15, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an additional purchase by the U.S. government for its neutralizing antibody therapies authorized for emerge...

1 week ago - PRNewsWire

Lilly to Participate in the 2021 Cantor Virtual Global Healthcare Conference

INDIANAPOLIS, Sept. 13, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021.

1 week ago - PRNewsWire

Lilly to Present New Data from Oncology Portfolio at ESMO Congress

INDIANAPOLIS, Sept. 13, 2021 /PRNewswire/ -- New data from various studies of Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib), Retevmo® (selpercatinib) and CYRAMZA® (ramucirumab) will be pre...

1 week ago - PRNewsWire

Why Eli Lilly's COVID Antibody Therapy Is Making a Comeback

There's a one-word answer: delta.

2 weeks ago - The Motley Fool

Lilly's (LLY) Jardiance Gets Breakthrough Therapy Tag for HFpEF

The FDA bestows a Breakthrough Therapy status on Lilly's (LLY) Jardiance for heart failure with preserved ejection fraction (HFpEF).

2 weeks ago - Zacks Investment Research

Here's Why ProQR Stock Surged on Thursday

A new collaboration deal with Eli Lilly could be worth up to $1.3 billion.

Other symbols:PRQR
2 weeks ago - The Motley Fool

Lilly Prices First Sustainability Bond to Advance Global ESG Strategy

INDIANAPOLIS, Sept. 9, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the pricing of its first sustainability bond to advance its global environmental, social and governance (ESG...

2 weeks ago - PRNewsWire

Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction (H...

INGELHEIM, Germany & INDIANAPOLIS--(BUSINESS WIRE)--Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction (HFpEF)

2 weeks ago - Business Wire

Eli Lilly Inks Another RNA Collab, This Time With ProQR

Eli Lilly And Co (NYSE: LLY) is doubling down on RNA research as it pens another pact with a quiet RNA editing player focused on neuroscience, ProQR Therapeutics N.V. (NASDAQ: PRQR).

2 weeks ago - Benzinga

Lilly Diabetes joins The Leona M. and Harry B.

INDIANAPOLIS, Sept. 7, 2021 /PRNewswire/ -- Lilly Diabetes will commit nearly $1 million over the next three years in a joint effort with The Leona M.

2 weeks ago - PRNewsWire

Lilly Announces Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt ...

INDIANAPOLIS, Sept. 7, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has commenced a cash tender offer for up to $1.5 billion combined aggregate principal amount (the "T...

2 weeks ago - PRNewsWire